$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000142545019000090 Filed on November 08, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$18.95M	$20.74M	$14.57M
YoY Change	30.09%	31.13%	24.72%
Cost Of Revenue	$4.500M	$4.849M	$4.050M
YoY Change	11.11%	26.18%	-54.14%
Gross Profit	$14.45M	$15.90M	$10.51M
YoY Change	37.44%	32.71%	19.04%
Gross Profit Margin	76.25%	76.62%	72.17%
Selling, General & Admin	$15.58M	$16.04M	$11.10M
YoY Change	40.36%	33.35%	-8.26%
% of Gross Profit	107.82%	100.9%	105.57%
Research & Development	$1.910M	$1.396M	$1.280M
YoY Change	49.22%	24.42%	36.17%
% of Gross Profit	13.22%	8.78%	12.17%
Depreciation & Amortization	$1.410M	$1.350M	$710.0K
YoY Change	98.59%	73.08%	7.58%
% of Gross Profit	9.76%	8.49%	6.75%
Operating Expenses	$17.48M	$17.43M	$12.38M
YoY Change	41.2%	32.59%	-5.06%
Operating Profit	-$3.031M	-$1.539M	-$1.866M
YoY Change	62.43%	31.31%	-55.61%
Interest Expense	-$1.310M	-$1.300M	-$530.0K
YoY Change	147.17%	113.11%	-15.87%
% of Operating Profit
Other Income/Expense, Net	$10.00K	-$1.338M	-$70.00K
YoY Change	-114.29%	93.07%	600.0%
Pretax Income	-$4.329M	-$2.877M	-$2.470M
YoY Change	75.26%	53.85%	-49.07%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$5.429M	-$2.664M	-$2.468M
YoY Change	119.98%	42.84%	-49.06%
Net Earnings / Revenue	-28.65%	-12.84%	-16.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$361.0K	-$181.7K	-$189.7K
COMMON SHARES
Basic Shares Outstanding	14.97M shares	14.94M shares	12.81M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.80M	$19.70M	$60.70M
YoY Change	16.64%	-19.59%	42.49%
Cash & Equivalents	$70.78M	$19.67M	$60.69M
Short-Term Investments
Other Short-Term Assets	$2.800M	$39.80M	$1.300M
YoY Change	115.38%	3880.0%	62.5%
Inventory	$38.00M	$34.53M	$25.71M
Prepaid Expenses
Receivables	$16.00M	$14.18M	$8.999M
Other Receivables	$600.0K	$500.0K	$500.0K
Total Short-Term Assets	$128.1M	$108.7M	$97.16M
YoY Change	31.81%	75.8%	39.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.35M	$21.53M	$12.77M
YoY Change	67.21%	68.56%	22.88%
Goodwill	$13.77M	$10.73M	$0.00
YoY Change
Intangibles			$2.181M
YoY Change			-7.15%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$54.10M	$23.17M	$2.181M
YoY Change	2380.33%	54.13%	-82.88%
TOTAL ASSETS
Total Short-Term Assets	$128.1M	$108.7M	$97.16M
Total Long-Term Assets	$54.10M	$23.17M	$2.181M
Total Assets	$182.2M	$153.4M	$112.1M
YoY Change	62.49%	99.57%	36.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.467M	$7.746M	$3.971M
YoY Change	62.86%	31.22%	-27.73%
Accrued Expenses	$4.300M	$3.900M	$3.600M
YoY Change	19.44%	18.18%	24.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$30.00M	$0.00
YoY Change
Long-Term Debt Due	$124.0K	$30.12M	$118.0K
YoY Change	5.08%	25646.15%	4.42%
Total Short-Term Liabilities	$13.66M	$46.18M	$9.217M
YoY Change	48.24%	323.09%	-2.64%
LONG-TERM LIABILITIES
Long-Term Debt	$26.07M	$21.09M	$21.16M
YoY Change	23.21%	-16.56%	-16.51%
Other Long-Term Liabilities	$63.00K	$45.00K	$0.00
YoY Change
Total Long-Term Liabilities	$26.13M	$21.14M	$21.16M
YoY Change	23.51%	-16.39%	-16.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.66M	$46.18M	$9.217M
Total Long-Term Liabilities	$26.13M	$21.14M	$21.16M
Total Liabilities	$39.79M	$67.32M	$30.37M
YoY Change	31.01%	86.0%	-12.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.8M	-$123.4M	-$115.1M
YoY Change	11.93%	9.56%	0.0%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$142.4M	$86.11M	$81.73M
YoY Change
Total Liabilities & Shareholders Equity	$182.2M	$153.4M	$112.1M
YoY Change	62.49%	99.57%	36.21%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$5.429M	-$2.664M	-$2.468M
YoY Change	119.98%	42.84%	-49.06%
Depreciation, Depletion And Amortization	$1.410M	$1.350M	$710.0K
YoY Change	98.59%	73.08%	7.58%
Cash From Operating Activities	-$6.930M	-$430.0K	-$2.720M
YoY Change	154.78%	-63.87%	-18.32%
INVESTING ACTIVITIES
Capital Expenditures	-$1.380M	-$2.030M	$50.00K
YoY Change	-2860.0%	75.0%	-104.0%
Acquisitions
YoY Change
Other Investing Activities	-$150.0K	$280.0K	-$500.0K
YoY Change	-70.0%
Cash From Investing Activities	-$1.530M	-$1.730M	-$460.0K
YoY Change	232.61%	49.14%	-63.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	59.97M	450.0K	39.42M
YoY Change	52.13%	50.0%	-12.24%
NET CHANGE
Cash From Operating Activities	-6.930M	-430.0K	-2.720M
Cash From Investing Activities	-1.530M	-1.730M	-460.0K
Cash From Financing Activities	59.97M	450.0K	39.42M
Net Change In Cash	51.51M	-1.710M	36.24M
YoY Change	42.14%	-16.59%	-10.16%
FREE CASH FLOW
Cash From Operating Activities	-$6.930M	-$430.0K	-$2.720M
Capital Expenditures	-$1.380M	-$2.030M	$50.00K
Free Cash Flow	-$5.550M	$1.600M	-$2.770M
YoY Change	100.36%	-5433.33%	33.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14967128	shares
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19669000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	60691000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	365000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14182000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8999000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	34533000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25708000	USD
CY2019Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	545000	USD
CY2018Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	502000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1623000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1256000	USD
CY2019Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	38168000	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	108720000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	97156000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21532000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12768000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10200000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1921000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	10732000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2240000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2019Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	23172000	USD
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2181000	USD
CY2019Q3	us-gaap	Assets Assets	153424000	USD
CY2018Q4	us-gaap	Assets Assets	112105000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7746000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3971000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3858000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3552000	USD
CY2019Q3	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	123000	USD
CY2018Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	118000	USD
CY2019Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30000000	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3085000	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1372000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1576000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	46184000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9217000	USD
CY2019Q3	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21090000	USD
CY2018Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21156000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21135000	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21156000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	67319000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	30373000	USD
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14967128	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14967128	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	210479000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197442000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123393000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-985000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-623000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	86105000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153424000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112105000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20744000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15820000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22924000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20005000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53600000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42991000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4849000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3843000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13431000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10825000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	15895000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	11977000	USD
	us-gaap	Gross Profit GrossProfit	40169000	USD
	us-gaap	Gross Profit GrossProfit	32166000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8771000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7150000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7267000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4877000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19448000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16393000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1396000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1122000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3843000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3455000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	17434000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	13149000	USD
	us-gaap	Operating Expenses OperatingExpenses	46215000	USD
	us-gaap	Operating Expenses OperatingExpenses	39853000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1539000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1172000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6046000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7687000	USD
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1297000	USD
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-608000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2232000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1722000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-41000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-85000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-148000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1338000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-693000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2310000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1870000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2877000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1865000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8356000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9557000	USD
CY2019Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	213000	USD
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	54000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2664000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1865000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1865000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8302000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9557000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2664000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1865000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1865000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8302000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9557000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14639020	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12624858	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14487015	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12417972	shares
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-2664000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1865000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8302000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9557000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-530000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-101000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-362000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-478000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-530000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-101000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-362000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-478000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3194000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1966000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8664000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10035000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	565000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	692000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	471000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-133000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10000000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	88082000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-2664000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-530000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	484000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	733000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	86105000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	47495000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	82000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2177000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	44754000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2692000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-459000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	454000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	42057000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1865000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-101000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	326000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	268000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	40685000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8302000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9557000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3258000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2177000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1896000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2899000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	5126000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	4077000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6491000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5274000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	360000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	214000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3680000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	408000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	798000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-1000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	15000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11433000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12855000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	590000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10843000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12855000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	49687000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	170000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	195000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10536000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5311000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60393000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5506000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	88000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	84000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	30000000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1141000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	326000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31053000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	242000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40183000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18119000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	60691000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	42582000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	20508000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	24463000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	839000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19669000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24463000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2232000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1722000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	593000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	1061000	USD
	us-gaap	Stock Issued1 StockIssued1	10000000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:4.22pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:4.22pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform \| Femur and Orthex, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. In September 2018, we further expanded operations in Canada selling direct to local hospitals, and in January 2019 we expanded to Belgium and the Netherlands. Additionally, in March 2019 we established a holding company and an operating company in the Netherlands that are expected to enhance our operations in Europe. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On June 4, 2019, we purchased all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. ("Vilex") and all the issued and outstanding units of membership interests in Orthex, LLC ("Orthex") for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as Orthex Hexapod technology which is used to treat pediatrics congenital deformities and limb length discrepancies. Because the current products of Vilex also include adult offerings that are not core to the Company's pediatrics business, the Company has begun taking steps to divest the non-core Vilex assets. The Company anticipates completing the divestiture by the end of 2019. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123393000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	40.76
CY2019Q2	kids	Business Combination Escrow Deposit Maximum Term BusinessCombinationEscrowDepositMaximumTerm	P20M
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	737000	USD
CY2019Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	148000	USD
CY2019Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1285000	USD
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1699000	USD
CY2019Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	707000	USD
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1213000	USD
CY2019Q3	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	365000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	432000	USD
CY2019Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	213000	USD
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	54000	USD
CY2019Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	213000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	54000	USD
CY2019Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	30000000	USD
CY2018Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2019Q3	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	51213000	USD
CY2018Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	21274000	USD
CY2019Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	30123000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000	USD
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21090000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21156000	USD
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1297000	USD
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-608000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2232000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1722000	USD
	us-gaap	Royalty Expense RoyaltyExpense	115000	USD
	us-gaap	Royalty Expense RoyaltyExpense	108000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	87345000	USD
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	335000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation	16200000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	1062000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	2302000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	22430000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	112094	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.32
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M18D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38920	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	29.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2546	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	27.61
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	70628	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.97
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M24D
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6790	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	27.81
	kids	Class Of Warrant Or Right Forfeited Or Expired ClassOfWarrantOrRightForfeitedOrExpired	6386	shares
	kids	Class Of Warrant Or Right Forfeited Or Expired Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightForfeitedOrExpiredWeightedAverageExercisePriceOfWarrantsOrRights	0
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	404	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2019Q3	kids	Classof Warrantor Right Exercised ClassofWarrantorRightExercised	0	shares
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2664000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1865000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8302000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9557000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14639020	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12624858	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14487015	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12417972	shares
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	388534	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	307881	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20744000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15820000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53600000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42991000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20744000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15820000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53600000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42991000	USD
CY2018Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2019Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	69000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70000	USD
	kids	Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment	500000	USD

Files In Submission

Name	View Source	Status
0001425450-19-000090-index-headers.html	Edgar Link	pending
0001425450-19-000090-index.html	Edgar Link	pending
0001425450-19-000090.txt	Edgar Link	pending
0001425450-19-000090-xbrl.zip	Edgar Link	pending
exhibit311-ceocertific.htm	Edgar Link	pending
exhibit312-cfocertific.htm	Edgar Link	pending
exhibit321-ceocertific.htm	Edgar Link	pending
exhibit322-cfocertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20190930.htm	Edgar Link	pending
kids-20190930.xsd	Edgar Link	pending
kids-20190930_cal.xml	Edgar Link	unprocessable
kids-20190930_def.xml	Edgar Link	unprocessable
kids-20190930_htm.xml	Edgar Link	completed
kids-20190930_lab.xml	Edgar Link	unprocessable
kids-20190930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2019 Q4 Form 10-Q Financial Statement

#000142545019000090 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2019 Q4 Form 10-Q Financial Statement

#000142545019000090 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids